1426899-73-1

Basic information

• Product Name: 2-(5-fluoro-pyridin-3-yl)-6-hydroxy-chroman-4-one
• Synonyms: 2-(5-fluoro-pyridin-3-yl)-6-hydroxy-chroman-4-one
• CAS NO: 1426899-73-1
• Molecular Weight: 259.237
• Mol File: 1426899-73-1.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 2-(5-fluoro-pyridin-3-yl)-6-hydroxy-chroman-4-one(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(5-fluoro-pyridin-3-yl)-6-hydroxy-chroman-4-one(1426899-73-1)
• EPA Substance Registry System: 2-(5-fluoro-pyridin-3-yl)-6-hydroxy-chroman-4-one(1426899-73-1)

Safety Data

• Hazardous Substances Data: 1426899-73-1(Hazardous Substances Data)

Upstream product

• 39891-04-8 5-fluoropyridine-3-carboxaldehyde 
• 131341-58-7 2,5'-dihydroxy acetophenone 
• 490-78-8 2,5-Dihydroxyacetophenone 

Relevant articles and documents

Substd. 2 - (chromane-6-carbonoyloxysilane) and its use as medicine iminothiazole-

PROBLEM TO BE SOLVED: To provide: a compound usable for disorders such as arrhythmia, cardiac failure and cerebral apoplexy caused by disturbance of intracellular calcium homeostasis of sodium-calcium exchanger (NCX), especially sodium-calcium exchanger of subtype 1 (NCX1); production method of the compound; use thereof as a pharmaceutical; and a pharmaceutical composition including the compound.SOLUTION: There is disclosed a substituted 2-(chroman-6-yloxy)-thiazole compound expressed by general formula I.

Substituted 2-(chroman-6-yloxy)-thiazoles and their use as pharmaceuticals

Substituted 2-(chroman-6-yloxy)-thiazoles and their use as pharmaceuticals The present invention relates to substituted 2-(chroman-6-yloxy)-thiazoles of the formula I, in which Ar, R2, R3 and R4 are as defined in the claims. The compounds of the formula I are inhibitors of the sodium-calcium exchanger (NCX), especially of the sodium-calcium exchanger of subtype 1 (NCX1), and are suitable for the treatment of diverse disorders in which intracellular calcium homeostasis is disturbed, such as arrhythmias, heart failure and stroke. The invention furthermore relates to processes for the preparation of the compounds of the formula I, their use as pharmaceuticals, and pharmaceutical compositions comprising them.